Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
4.860
-0.020 (-0.41%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Intensity Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 9.53 | 11.92 | 2.59 | 8.56 | 1.31 | 4.54 |
Short-Term Investments | - | - | - | 6.22 | - | - |
Cash & Short-Term Investments | 9.53 | 11.92 | 2.59 | 14.78 | 1.31 | 4.54 |
Cash Growth | 330.01% | 360.27% | -82.47% | 1026.22% | -71.10% | -51.28% |
Other Receivables | - | - | - | - | - | 0.05 |
Receivables | - | - | - | - | - | 0.05 |
Prepaid Expenses | 1.7 | 0.79 | 0.77 | 0.69 | 0.06 | 0.07 |
Other Current Assets | - | - | - | - | 0.08 | 0.07 |
Total Current Assets | 11.23 | 12.71 | 3.36 | 15.46 | 1.45 | 4.73 |
Property, Plant & Equipment | 0.08 | 0.1 | 0.12 | 0.15 | 0.14 | 0.32 |
Other Long-Term Assets | 0.21 | 1.3 | 1.3 | 1.68 | 0.17 | 0.17 |
Total Assets | 11.52 | 14.1 | 4.78 | 17.3 | 1.76 | 5.22 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.01 | 0.58 | 1.22 | 3.05 | 0.6 | 0.17 |
Accrued Expenses | 1.2 | 1.53 | 0.51 | 0.89 | 0.33 | 0.34 |
Short-Term Debt | - | - | - | - | 4.35 | 2.02 |
Current Portion of Leases | 0.03 | 0.03 | 0.03 | 0.02 | 0.14 | 0.18 |
Other Current Liabilities | - | - | - | - | 1.39 | 1.01 |
Total Current Liabilities | 2.25 | 2.15 | 1.76 | 3.96 | 6.82 | 3.72 |
Long-Term Leases | 0.06 | 0.08 | 0.11 | 0.14 | - | 0.14 |
Other Long-Term Liabilities | - | - | - | 0.04 | 0.04 | 0.04 |
Total Liabilities | 2.31 | 2.23 | 1.87 | 4.13 | 6.86 | 3.9 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | - | - | - | 0 | - | 0 |
Additional Paid-In Capital | 93.04 | 90.27 | 69.7 | 63.68 | 23.56 | 22.39 |
Retained Earnings | -83.83 | -78.39 | -66.78 | -50.52 | -38.65 | -31.07 |
Total Common Equity | 9.21 | 11.88 | 2.92 | 13.16 | -15.1 | -8.68 |
Shareholders' Equity | 9.21 | 11.88 | 2.92 | 13.16 | -5.1 | 1.32 |
Total Liabilities & Equity | 11.52 | 14.1 | 4.78 | 17.3 | 1.76 | 5.22 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.1 | 0.11 | 0.14 | 0.16 | 4.49 | 2.34 |
Net Cash (Debt) | 9.43 | 11.81 | 2.45 | 14.62 | -3.18 | 2.2 |
Net Cash Growth | 351.17% | 381.69% | -83.23% | - | - | -75.09% |
Net Cash Per Share | 4.06 | 8.71 | 4.41 | 42.41 | -23.31 | 16.10 |
Filing Date Shares Outstanding | 3.26 | 2.54 | 0.61 | 0.55 | 0.14 | 0.14 |
Total Common Shares Outstanding | 2.95 | 2.52 | 0.6 | 0.55 | 0.14 | 0.14 |
Working Capital | 8.98 | 10.56 | 1.61 | 11.51 | -5.37 | 1.01 |
Book Value Per Share | 3.13 | 4.70 | 4.82 | 24.00 | -110.69 | -63.67 |
Tangible Book Value | 9.21 | 11.88 | 2.92 | 13.16 | -15.1 | -8.68 |
Tangible Book Value Per Share | 3.13 | 4.70 | 4.82 | 24.00 | -110.69 | -63.67 |